RxDoctor Payments Data

Emad Botros, MD

Internal Medicine · Winchester, VANPI 1528063070

Payments from drug & device makers

$445in general payments, 2019–2025

Across 7 payments — averaging $63.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Stryker$142
  • Medtronic$126
  • Novo Nordisk$116
  • GSK$48
  • Dentsply Sirona Inc$13

What the payments were for

  • Food & beverage$445100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Stryker1$142
Medtronic2$126
Novo Nordisk1$116
GSK2$48
Dentsply Sirona Inc1$13

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$445 in reported general payments places this provider in the 65th percentile of 2,724 internal medicine providers in Virginia.

See all internal medicine providers in Virginia

Medicare billing

Part B allowed, 2024
$316,570
Medicare patients
811
Services billed
6,650

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban214$193,163
OzempicSemaglutide85$123,199
JardianceEmpagliflozin92$98,078
TrulicityDulaglutide32$61,380
XareltoRivaroxaban50$51,330
RybelsusSemaglutide19$32,733
Tresiba Flextouch U-200Insulin Degludec11$28,679
Repatha SureclickEvolocumab26$18,522
JanuviaSitagliptin Phosphate12$15,495
Tresiba Flextouch U-100Insulin Degludec13$14,589
Bydureon BciseExenatide Microspheres14$12,378
Trelegy ElliptaFluticasone/Umeclidin/Vilanter21$11,810
Breo ElliptaFluticasone/Vilanterol15$8,051
Breztri AerosphereBudesonide/Glycopyr/Formoterol12$7,094
Rosuvastatin Calcium585$5,825

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$116$155,932104 claims
GSKTrelegy Ellipta, Breo Ellipta$48$19,86136 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 2,724 internal medicine providers in Virginia.

Other internal medicine in Winchester

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →